INTERLEUKIN-13 RECEPTOR ALPHA 2 PEPTIDE-BASED BRAIN CANCER VACCINES
Provided herein are interleukin-13 receptor α2 peptide-based brain cancer vaccines and methods for treating and vaccinating against brain cancer comprising administering to patients in need thereof interleukin-13 receptor α2 peptide-based brain cancer vaccines. Also provided herein are regimens comprising interleukin-13 receptor α2 peptides and at least one additional peptide and/or immunostimulant.
1 . A pharmaceutical composition comprising an IL-13Rα2 peptide, an EphA2 peptide, a survivin peptide, and a WT1 peptide.
2 . A pharmaceutical composition comprising an IL-13Rα2 peptide, an EphA2 peptide, and a survivin peptide.
3 . A pharmaceutical composition comprising an IL-13Rα2 peptide, an EphA2 peptide, YKL-40 peptide, and a GP100 peptide.
4 . The pharmaceutical composition of claim 1 , wherein the IL-13Rα2 peptide comprises any one of SEQ ID NOs:1-4, the EphA2 peptide comprises SEQ ID NO:6, the survivin peptide comprises SEQ ID NO:7, and the WT1 peptide comprises SEQ ID NO:8.
5 . The pharmaceutical composition of claim 2 , wherein the IL-13Rα2 peptide comprises any one of SEQ ID NOs:1-4, the EphA2 peptide comprises SEQ ID NO:6, and the survivin peptide comprises SEQ ID NO:7.
6 . The pharmaceutical composition of claim 3 , wherein the IL-13Rα2 peptide comprises any one of SEQ ID NOs:1-4, the EphA2 peptide comprises SEQ ID NO:6, the YKL-40 peptide comprises SEQ ID NO:10, and the GP100 peptide comprises SEQ ID NO:11.
7 . The pharmaceutical composition of claim 1 , wherein one or more of the peptides are loaded on dendritic cells.
8 . The pharmaceutical composition of claim 1 , further comprising an adjuvant.
9 . The pharmaceutical composition of claim 8 , wherein the adjuvant is Montanide ISA-51.
10 . A method for treating, preventing, or managing brain cancer in a subject in need thereof comprising administering to said subject the pharmaceutical composition of claim 1 .
11 . The method of claim 10 , further comprising administering to the subject a helper T cell epitope.
12 . The method of claim 11 , wherein the helper T cell epitope is the PADRE peptide, a Tetanus toxoid peptide, or the HBV 128-140 core peptide.
13 . The method of claim 10 , further comprising administering to the subject an immune response modifier.
14 . The method of claim 13 , wherein the immune response modifier is poly-ICLC or imiquimod.
15 . The method of claim 10 , wherein the subject is human.
16 . The method of claim 10 , wherein the pharmaceutical composition is administered to the subject subcutaneously or intra-nodally.
17 . A method for treating, preventing, or managing brain cancer in a subject in need thereof comprising administering to said subject (i) a first pharmaceutical composition comprising an IL-13Rα2 peptide, an EphA2 peptide, a survivin peptide, a WT1 peptide, a helper T cell epitope, and an adjuvant; and (ii) a second pharmaceutical composition comprising an immune response modifier.
18 . A method for treating, preventing, or managing brain cancer in a subject in need thereof comprising administering to said subject (i) a first pharmaceutical composition comprising an IL-13Rα2 peptide, an EphA2 peptide, a survivin peptide, a helper T cell epitope, and an adjuvant; and (ii) a second pharmaceutical composition comprising an immune response modifier.
19 . A method for treating, preventing, or managing brain cancer in a subject in need thereof comprising administering to said subject (i) a first pharmaceutical composition comprising an IL-13Rα2 peptide loaded on a dendritic cell, an EphA2 peptide loaded on a dendritic cell, a YKL-40 peptide loaded on a dendritic cell, a GP100 peptide loaded on a dendritic cell, and a helper T cell epitope; and (ii) a second pharmaceutical composition comprising an immune response modifier.
20 . A pharmaceutical composition comprising an IL-13Rα2 peptide, an EphA2 peptide, and another peptide.
21 . The pharmaceutical composition of claim 20 in which the other peptide is a survivin peptide.
22 . The pharmaceutical composition of claim 20 in which the other peptide is a WT1 peptide.
23 . The pharmaceutical composition of claim 20 in which the other peptide is a YKL-40 peptide.
24 . The pharmaceutical composition of claim 20 in which the other peptide is a GP100 peptide.
25 . A method of vaccinating a patient against glioma, wherein a composition comprising EphA2 883-891 is introduced into the patient under conditions sufficient for the patient to develop a CTL response.
26 . The pharmaceutical composition of claim 2 , wherein one or more of the peptides are loaded on dendritic cells.
27 . The phai naceutical composition of claim 3 , wherein one or more of the peptides are loaded on dendritic cells.
28 . The pharmaceutical composition of claim 2 , further comprising an adjuvant.
29 . The pharmaceutical composition of claim 28 , wherein the adjuvant is Montanide ISA-51.
30 . The pharmaceutical composition of claim 3 , further comprising an adjuvant.
31 . The pharmaceutical composition of claim 30 , wherein the adjuvant is Montanide ISA-51.
32 . A method for treating, preventing, or managing brain cancer in a subject in need thereof comprising administering to said subject the pharmaceutical composition of claim 2 .
33 . The method of claim 32 , further comprising administering to the subject a helper T cell epitope.
34 . The method of claim 33 , wherein the helper T cell epitope is the PADRE peptide, a Tetanus toxoid peptide, or the HBV 128-140 core peptide.
35 . The method of claim 32 , further comprising administering to the subject an immune response modifier.
36 . The method of claim 35 , wherein the immune response modifier is poly-ICLC or imiquimod.
37 . The method of claim 32 , wherein the subject is human.
38 . The method of claim 32 , wherein the pharmaceutical composition is administered to the subject subcutaneously or intra-nodally.
39 . A method for treating, preventing, or managing brain cancer in a subject in need thereof comprising administering to said subject the pharmaceutical composition of claim 3 .
40 . The method of claim 39 , further comprising administering to the subject a helper T cell epitope.
41 . The method of claim 40 , wherein the helper T cell epitope is the PADRE peptide, a Tetanus toxoid peptide, or the HBV 128-140 core peptide.
42 . The method of claim 39 , further comprising administering to the subject an immune response modifier.
43 . The method of claim 42 , wherein the immune response modifier is poly-ICLC or imiquimod.
44 . The method of claim 39 , wherein the subject is human.
45 . The method of claim 39 , wherein the pharmaceutical composition is administered to the subject subcutaneously or intra-nodally.